hydralazine has been researched along with Dysmyelopoietic Syndromes in 2 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day." | 2.76 | Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. ( Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011) |
| "Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day." | 1.46 | Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). ( Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Candelaria, M | 2 |
| Burgos, S | 1 |
| Ponce, M | 1 |
| Espinoza, R | 1 |
| Dueñas-Gonzalez, A | 2 |
| Herrera, A | 1 |
| Labardini, J | 1 |
| González-Fierro, A | 1 |
| Trejo-Becerril, C | 1 |
| Taja-Chayeb, L | 1 |
| Pérez-Cárdenas, E | 1 |
| de la Cruz-Hernández, E | 1 |
| Arias-Bofill, D | 1 |
| Vidal, S | 1 |
| Cervera, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydralazine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DN | 2011 |
1 other study available for hydralazine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Tr | 2017 |